生物活性基复合水凝用于心肌梗塞治疗:ROS清除和血管生成调节
Qiuhao Luo1, Zhanshan Gao1, Long Bai2
1National Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu, 610064, People's Republic of China.
Acta biomaterialia
|March 22, 2025
概括
这项研究开发了一种新的水凝系统,使用抗氧化剂和亲血管性来修复心肌梗塞 (MI) 后的心脏组织. 可注射凝有效降低氧化应激,促进血管生长,以快速修复心脏.
科学领域:
- 生物材料科学 生物材料科学
- 心血管研究研究心血管研究
- 再生医学是一种再生医学.
背景情况:
- 心肌梗塞 (MI) 导致缺血,缺氧和心肌细胞死亡,导致痕组织的形成.
- 恢复血液 perfusion 和减少反应性氧物种 (ROS) 对于修复受损的心脏组织至关重要.
- 目前治疗心肌梗塞的方法往往不能有效地促进心肌再生.
研究的目的:
- 开发一种可注射的水凝系统,结合抗氧化剂和亲血管性,用于最小侵入性心脏修复.
- 评估双作用在清除ROS和促进MI后血管生成方面的有效性.
- 评估该系统在预防心肌细胞亡,炎症和心肌纤维化方面的潜力.
主要方法:
- 合成了具有抗氧化特性的MMP12 (YWDAW) 和具有亲血管生成作用的KRX (MRPYDANKR) .
- 将这些生物活性加载到可注射的GelMA水凝中,以便在MI部位持续释放.
- 进行了体内和体外实验,以评估水凝对受损的心肌组织的治疗作用.
主要成果:
- 酸载荷的水凝有效地清除了ROS,并促进了血管生成.
- 该系统证明了长期抑制细胞亡和炎症.
- 观察到心肌纤维化显著减少,心脏组织受损的快速修复.
- 在体内和体外的研究都证实了联合方法的治疗益处.
结论:
- 在可注射水凝中,抗氧化剂和亲血管性的组合为心肌中风后的心肌修复提供了有前途的治疗策略.
- 这种生物活性水凝系统通过解决关键的病理过程,促进心脏组织再生.
- 化学合成的和水凝矩阵为可扩展的制造和心血管治疗中的广泛生物医学应用提供了基础.
更多相关视频
06:15A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.
Published on: June 14, 2015
8.7K
09:19Intramyocardial Transplantation of MSC-Loading Injectable Hydrogels after Myocardial Infarction in a Murine Model
Published on: September 20, 2020
4.4K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...